Amylyx CFO James M. Frates sells 40,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates exercised options for 20,000 common shares at $6.88 per share on November 9 and another 20,000 on November 10, 2026. He sold 20,000 shares on each date: 7,700 at a weighted average $29.3887 and 12,300 at $30.1105 on November 9; 12,800 at $30.3209 and 7,200 at $30.9698 on November 10. The transactions were effected under a Rule 10b5-1 trading plan adopted April 10, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 40,000 shares ($933K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
FRATES JAMES M
Role
Chief Financial Officer
Sold
40,000 shs ($1.21M)
Approx. gross sale proceeds
$1.21M
Approx. exercise cost
$275K
Approx. pre-tax spread
$933K
Share of Position Sold
14.6%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F10 | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 20,000 | $6.88 | $138K |
| Sale | Common Stock F1, F4 | 12,800 | $30.3209 | $388K |
| Sale | Common Stock F1, F5 | 7,200 | $30.9698 | $223K |
| Exercise | Stock Option (right to buy) F1, F10 | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 20,000 | $6.88 | $138K |
| Sale | Common Stock F1, F2 | 7,700 | $29.3887 | $226K |
| Sale | Common Stock F1, F3 | 12,300 | $30.1105 | $370K |
| Holding | Common Stock F6 | -- | -- | -- |
| Holding | Common Stock F7 | -- | -- | -- |
| Holding | Common Stock F8 | -- | -- | -- |
| Holding | Common Stock F9 | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 323,835 options (Direct);
Common Stock — 233,625 shares (Direct);
Common Stock — 166,531 shares (Indirect, By Trust)
Holdings Before and After:
Stock Option (right to buy), 363,835 to 323,835 options (Direct);
Common Stock, 233,625 to 233,625 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (10)
- F1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.82 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.905 to $31.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F6. Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F7. Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F8. Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F9. Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F10. This option is fully vested and exercisable.
Key Figures
Options exercised: 20,000 shares
Options exercised: 20,000 shares
Option exercise price: $6.88 per share
+5 more
8 metrics
Options exercised
20,000 shares
November 9, 2026
Options exercised
20,000 shares
November 10, 2026
Option exercise price
$6.88 per share
Options exercised on November 9 and November 10, 2026
Shares sold and weighted-average price
7,700 shares at $29.3887 per share
November 9, 2026
Shares sold and weighted-average price
12,300 shares at $30.1105 per share
November 9, 2026
Shares sold and weighted-average price
12,800 shares at $30.3209 per share
November 10, 2026
Shares sold and weighted-average price
7,200 shares at $30.9698 per share
November 10, 2026
Plan adoption date
April 10, 2026
Rule 10b5-1 trading plan covering the reported transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), fully vested and exercisable
4 terms
Rule 10b5-1 trading plan regulatory
"Rule 10b5-1 trading plan adopted on April 10, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"Stock Option (right to buy)"
fully vested and exercisable financial
"This option is fully vested and exercisable"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AMLX options did the CFO exercise, and at what price?
James M. Frates exercised options for 20,000 common shares at $6.88 per share on each of November 9 and November 10, 2026. The reported option was fully vested and exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
